The full-body scan comes to Manhattan with $700 million. The business is the second scan.

Neko Health, the Stockholm company co-founded by Spotify's founder, announced a $700 million Series C today, led by Lightspeed, ahead of a US launch beginning in New York later this year. When we wrote about its $260 million round in January 2025, the company had scanned about 10,000 people. It now says more than 100,000 have been scanned in the UK and Sweden, that 350,000 are registered or waiting, and that about three in four members book and prepay their next scan before leaving the first one. The scan is £299 in Britain for an hour of skin imaging, blood tests, heart and vascular measurements; the US price is not announced but is to be comparable. Trade coverage puts the valuation near $7 billion, a figure the company did not confirm. The investor list includes a long roster of athletes, entertainers and media founders. We are going to talk about the three-in-four.

Why the second scan is the company. A single scan of a healthy adult is a product; an annual scan is a subscription, and three-quarters of customers signing up for next year at the door is the metric a $700 million round is priced on. It is also where the evidence question lives. The company reports that most returning members with serious findings are now in good health or under control, and that five of seven key biomarkers improved between scans — figures from its own data, with no methodology, denominators or independent review published. Those may be true. They are also precisely the claims a company whose revenue depends on the second scan would make, and the reader cannot check them.

Ben’s take

Three in four prepaying is an extraordinary retention number for a consumer product, and investors are right to value it. The reason it is that high is the reason this site exists: a scan of a healthy person reliably finds something — a mole to watch, a value to recheck — and a finding is the most effective renewal mechanism ever devised. The company does not need to overpromise. It needs the scan to produce a reason to come back, and biology obliges.

Loree’s take

A well-run hour with a clinician who checks your skin, blood pressure, lipids and glucose is a good thing, and if a £299 scan gets people who avoid doctors to do it once a year, I will not argue. What I will argue with is the frame: that the scan knows something your doctor doesn't, and that the findings in a healthy body need a second scan rather than a conversation. Most of what it finds in my patients is already in their chart. The rest is usually nothing, and nothing is hard to sell twice.

Why it matters to a recovering optimizer. The scan is arriving in the city with the highest concentration of our readers, with celebrity investors and a waiting list. Before you join it, write down what you would do differently with a result. If the answer is see your doctor, you can do that for a copay. If the answer is book the next scan, you have just described the business model.